Psilocybin: Clinical Trials
The question
To ask the Secretary of State for Health and Social Care, what the conclusive findings were of the Government-funded psilocybin trial that concluded in February 2024.
Answered by Dr Zubir Ahmed
The National Institute for Health and Care Research (NIHR) Clinician Scientist Fellowship titled ‘A Feasibility RCT of Single-Dose Psilocybin in Unipolar Depressive Disorder Resistant to Standard Treatments’ is shown on the NIHR Funding and Awards website as concluding in February 2024. The progress of this award was significantly delayed by the COVID-19 pandemic. The results are therefore not yet available and are due to be released in 2026.
The main aim of this award is to investigate the feasibility of conducting a trial in this patient group and to contribute towards the design of a more definitive study. The award has resulted in the creation of the Psychoactive Trials Group at King’s College London, which is one of the world’s most experienced clinical research teams in this emerging area of treatment.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →